Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Cardiometabolic Risk in Obesity and Pre-diabetes
NCT02681887Phase 3Unknown
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of melatonin in prediabetes, sponsored by Brigham and Women's Hospital. Primary endpoint: change in insulin sensitivity at 12 weeks. Status: unknown.
02
Drugs
melatonin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT02681887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681887.